Last updated on May 2020

A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate High or Very High Risk Myelodysplastic Syndrome (MDS).


Brief description of study

This Phase II is a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or intensive chemotherapy.

Clinical Study Identifier: NCT03946670

Find a site near you

Start Over

Highlands Oncology Group

Fayetteville, AR United States
  Connect »

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Novartis Investigative Site

Hospitalet de LLobregat, Spain
  Connect »

Novartis Investigative Site

Manchester, United Kingdom
  Connect »

Novartis Investigative Site

Fayetteville, AR United States
  Connect »

Novartis Investigative Site

New Haven, CT United States
  Connect »

Novartis Investigative Site

Columbus, OH United States
  Connect »

Novartis Investigative Site

Houston, TX United States
  Connect »

Novartis Investigative Site

New Brunswick, NJ United States
  Connect »

Novartis Investigative Site

New York, NY United States
  Connect »

Novartis Investigative Site

Winston-Salem, NC United States
  Connect »

Novartis Investigative Site

Seattle, WA United States
  Connect »

Novartis Investigative Site

Atlanta, GA United States
  Connect »

Highlands Oncology Group

Fayetteville, AR United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.